Ron Lanton III, Esq

From supporting MTM services to reaching unhoused populations, the 340B program is a powerhouse for patient care, access, and affordability.

During his second term, President Trump has bolstered his approach at lowering prescription drug prices in the US through innovative yet unprecedented decisions.

Ron Lanton III, Esq, provides nuance to the current state of pharmacy sustainability and how the MFN drug pricing policy could impact the industry.

Ron Lanton III, Esq, discusses previous MFN drug pricing policies and why the free US drug market often yields higher patient costs.

Ron Lanton III, Esq, discusses the revamped version of the Trump Administration’s MFN drug pricing policy and why his second term may yield different outcomes.